stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Current ratio
Protagonist Therapeutics, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 21.7×, up 9.0× from fiscal 2025 (12.7×). Over the past ten years it has ranged from 3.5× (fiscal 2017) to 16.7× (fiscal 2023); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 12.7× | 1.83% |
| FY2024 | 12.5× | (25.32%) |
| FY2023 | 16.7× | 114.39% |
| FY2022 | 7.8× | 0.71% |
| FY2021 | 7.7× | (1.30%) |
| FY2020 | 7.8× | 91.10% |
| FY2019 | 4.1× | (21.92%) |
| FY2018 | 5.3× | 48.19% |
| FY2017 | 3.5× | (72.58%) |
| FY2016 | 12.9× | 184.65% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 21.7× | 22.26% |
| Mar 2026 | 17.8× | 39.70% |
| Dec 2025 | 12.7× | (2.59%) |
| Sep 2025 | 13.0× | (23.10%) |
| 37 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | 27.4× |
| PTGX Protagonist Therapeutics, Inc. | 21.7× |
| KRYS Krystal Biotech, Inc. compare | 7.9× |
| CAI Caris Life Sciences,�Inc. compare | 6.7× |
| IBRX ImmunityBio, Inc. compare | 5.7× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 3.1× |
| TWST Twist Bioscience Corporation compare | 2.7× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement